Insider Selling: Cadrenal Therapeutics (NASDAQ:CVKD) CFO Sells $69,233.01 in Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CFO Matthew Szot sold 9,933 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $6.97, for a total transaction of $69,233.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Cadrenal Therapeutics Stock Up 8.1%

Cadrenal Therapeutics stock opened at $7.33 on Friday. The firm has a 50 day moving average price of $10.12 and a 200-day moving average price of $11.72. Cadrenal Therapeutics, Inc. has a twelve month low of $6.42 and a twelve month high of $22.90. The company has a market capitalization of $17.15 million, a P/E ratio of -0.92 and a beta of 1.19.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.31) EPS for the quarter, beating the consensus estimate of ($1.55) by $0.24. Equities analysts expect that Cadrenal Therapeutics, Inc. will post -7.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $32.00.

Institutional Trading of Cadrenal Therapeutics

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. JPMorgan Chase & Co. bought a new position in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 7,500 shares of the company’s stock, valued at approximately $103,000. JPMorgan Chase & Co. owned 0.37% of Cadrenal Therapeutics as of its most recent SEC filing. 7.92% of the stock is currently owned by institutional investors.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.